CIP2A、c-Myc蛋白在食管鳞状细胞癌中的表达及其临床意义

Expression of CIP2A,c-Myc protein in esophageal squamous cell carcinoma and its clinical significance

目的研究CIP2A、c-Myc两种抑癌基因在食管鳞状细胞癌中的表达并分析两者之间及其与食管鳞状细胞癌各临床病理参数之间的关系。方法收集48例食管鳞状细胞癌组织标本及其相应癌旁组织标本,应用免疫组化方法对CIP2A、c-Myc蛋白的表达进行测定。结果在食管鳞状细胞癌组织、癌旁正常组织中CIP2A的表达阳性率分别为60.4%(29/48)和14.6%(7/48)。两者相比差异具有统计学意义(P<0.05);而c-Myc的表达阳性率分别为73.3%(33/48)和25.0%(12/48),两者差异显著,有统计学意义(P<0.05)。CIP2A蛋白的表达与病理分期、分级及淋巴结转移有关;c-Myc蛋白和表达量与病理分级及淋巴结转移相关,CIP2A和在食管鳞状细胞癌组织中表达呈正相关(P<0.05)。结论食管鳞状细胞癌中CIP2A与c-Myc蛋白的表达上调,两者之间相互作用并在食管鳞状细胞癌的发生发展中起重要作用,可能成为食管鳞状细胞癌的分子标记物或食管鳞状细胞癌治疗的新分子靶点。

Objective To investigate the expression of cancerous inhibitor of protein phosphatase 2A（CIP2A） and c-Myc in human esophageal squamous cell carcinoma and its relation with the clinicopathologic characteristics of the carcinoma.Methods Forty eight cases of esophageal squamous cell carcinoma tissues and adjacent normal tissues were collected.The expression of CIP2A and c-Myc protein were determined by immunihistochemical methods.Results The positive expression rates of CIP2A protein in esophageal squamous cell carcinoma tissues and adjacent normal gastric tissues 60.4%（29/48）and 14.6%（7/48）,which were statistically significant（P0.05）;The positive expression rates of in esophageal squamous cell carcinoma tissues and adjacent normal gastric tissues were 73.3%（33/48）and 25.0%（12/48）,which were statistically significant（P0.05）.The expression of was correlated with clinical pathological stage and histological differentiation and Lymph node metastasis.The expression of c-Myc was correlated with histological differentiation and lymph node metastasis.The expression of CIP2A was positively correlated with the expression of c-Myc protein in Esophageal squamous cell carcinoma（P0.05）.Conclusions Expression of CIP2A and c-Myc protein in esophageal squamous cell carcinoma play important roles in the development of esophageal squamous cell carcinoma,may become molecular markers of esophageal squamous cell carcinoma or new molecular targets for esophageal squamous cell carcinoma therapy.